Trial Profile

A Phase II Trial of NeuVax Adjuvant Treatment in Node Positive and Node Negative, HER2 1+, 2+ and 3+ Breast Cancer Patients.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 19 Feb 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nelipepimut-S (Primary)
Indications Breast cancer
Focus Therapeutic Use
Sponsors Phio Pharmaceuticals; RXi Pharmaceuticals

Most Recent Events

17 May 2018 According to a Sellas Life Sciences Group media release, the company will be conducting clinical and regulatory advisory board meetings at ASCO on May 30 and May 31 2018, based on the independent Data Safety Monitoring Board recommendation to seek regulatory guidance by the FDA.
30 May 2014 New trial record
06 Jun 2011 According to a RXi Pharmaceuticals media release, data presented at the American Society of Clinical Oncology (ASCO).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com